Patient characteristics of O-DLBCL and NO-DLBCL-GCB
| Characteristic . | PB-DLBCL (n = 41) . | Polyostotic-DLBCL (n = 14) . | Disseminated-DLBCL (n = 48) . | Extranodal NO-DLBCL-GCB (n = 16) . | Nodal NO-DLBCL-GCB (n = 19) . | Mixed NO-DLBCL-GCB (n = 28) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male sex | 24 | 59% | 9 | 64% | 32 | 67% | 10 | 63% | 13 | 68% | 18 | 64% |
| Median age (minimum-maximum), y | 54 (18-86) | 56 (13-73) | 63 (30-91) | 65 (46-82) | 67 (35-84) | 63 (44-95) | ||||||
| Ann Arbor stage | ||||||||||||
| I((X)E) | 29 | 71% | 0 | 0% | 0 | 0% | 4 | 25% | 2 | 11% | 0 | 0% |
| II((X)E) | 12 | 29% | 0 | 0% | 3 | 6% | 1 | 6% | 9 | 47% | 8 | 29% |
| III(E/S) | 0 | 0% | 0 | 0% | 3 | 6% | 0 | 0% | 8 | 42% | 2 | 7% |
| IV | 0 | 0% | 14 | 100% | 42 | 88% | 11 | 69% | 0 | 0% | 18 | 64% |
| IPI score | ||||||||||||
| 0-1 | 26 | 63% | 3 | 21% | 7 | 15% | 6 | 38% | 11 | 58% | 8 | 29% |
| 2-5 | 15 | 37% | 11 | 79% | 41 | 85% | 10 | 63% | 8 | 42% | 20 | 71% |
| First-line treatment | ||||||||||||
| R-CHOP +/− adjuvant radiotherapy* | 35 | 85% | 12 | 86% | 42 | 88% | 8 | 50% | 16 | 84% | 23 | 82% |
| Other chemotherapy ± adjuvant radiotherapy† | 4 | 10% | 2 | 14% | 4 | 8% | 0 | 0% | 1 | 5% | 3 | 11% |
| High-dose MTX‡ ± adjuvant radiotherapy | 0 | 0% | 0 | 0% | 0 | 0% | 7 | 44% | 0 | 0% | 0 | 0% |
| Palliative treatment§ | 2 | 5% | 0 | 0% | 2 | 4% | 1 | 6% | 2 | 11% | 2 | 7% |
| Response to first-line treatment | ||||||||||||
| CR | 37 | 90% | 14 | 100% | 36 | 75% | 11 | 69% | 14 | 74% | 18 | 64% |
| Non-CR | 4 | 10% | 0 | 0% | 12 | 25% | 5 | 31% | 5 | 26% | 10 | 36% |
| Median follow-up, mo | 50 | 53 | 37 | 33 | 17 | 22 | ||||||
| Characteristic . | PB-DLBCL (n = 41) . | Polyostotic-DLBCL (n = 14) . | Disseminated-DLBCL (n = 48) . | Extranodal NO-DLBCL-GCB (n = 16) . | Nodal NO-DLBCL-GCB (n = 19) . | Mixed NO-DLBCL-GCB (n = 28) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male sex | 24 | 59% | 9 | 64% | 32 | 67% | 10 | 63% | 13 | 68% | 18 | 64% |
| Median age (minimum-maximum), y | 54 (18-86) | 56 (13-73) | 63 (30-91) | 65 (46-82) | 67 (35-84) | 63 (44-95) | ||||||
| Ann Arbor stage | ||||||||||||
| I((X)E) | 29 | 71% | 0 | 0% | 0 | 0% | 4 | 25% | 2 | 11% | 0 | 0% |
| II((X)E) | 12 | 29% | 0 | 0% | 3 | 6% | 1 | 6% | 9 | 47% | 8 | 29% |
| III(E/S) | 0 | 0% | 0 | 0% | 3 | 6% | 0 | 0% | 8 | 42% | 2 | 7% |
| IV | 0 | 0% | 14 | 100% | 42 | 88% | 11 | 69% | 0 | 0% | 18 | 64% |
| IPI score | ||||||||||||
| 0-1 | 26 | 63% | 3 | 21% | 7 | 15% | 6 | 38% | 11 | 58% | 8 | 29% |
| 2-5 | 15 | 37% | 11 | 79% | 41 | 85% | 10 | 63% | 8 | 42% | 20 | 71% |
| First-line treatment | ||||||||||||
| R-CHOP +/− adjuvant radiotherapy* | 35 | 85% | 12 | 86% | 42 | 88% | 8 | 50% | 16 | 84% | 23 | 82% |
| Other chemotherapy ± adjuvant radiotherapy† | 4 | 10% | 2 | 14% | 4 | 8% | 0 | 0% | 1 | 5% | 3 | 11% |
| High-dose MTX‡ ± adjuvant radiotherapy | 0 | 0% | 0 | 0% | 0 | 0% | 7 | 44% | 0 | 0% | 0 | 0% |
| Palliative treatment§ | 2 | 5% | 0 | 0% | 2 | 4% | 1 | 6% | 2 | 11% | 2 | 7% |
| Response to first-line treatment | ||||||||||||
| CR | 37 | 90% | 14 | 100% | 36 | 75% | 11 | 69% | 14 | 74% | 18 | 64% |
| Non-CR | 4 | 10% | 0 | 0% | 12 | 25% | 5 | 31% | 5 | 26% | 10 | 36% |
| Median follow-up, mo | 50 | 53 | 37 | 33 | 17 | 22 | ||||||
CR, complete response; IPI, International Prognostic Index.
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; n = 136) and adjuvant radiotherapy (n = 47).
CHVmP/BV (cyclophosphamide, doxorubicin, teniposide, and prednisone with bleomycin and vincristine at mid-interval; n = 4), CHOP (N = 1), COPADM (cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate; n = 1), DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab; n = 5), PECC (prednisone, etoposide, chlorambucil, and lomustine; n = 1), RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, and prednisone; n = 1), RCVP (rituximab, cyclophosphamide, vincristine, prednisone; n = 1), and adjuvant radiotherapy (n = 9).
MATRIX (high-dose methotrexate [MTX], cytarabine, thiotepa, and rituximab)/BCNU (Carmustine)/autologous stem cell transplantation (n = 1), MBVP (high-dose MTX, BCNU, teniposide, and prednisone)/HD_araC (high-dose ara-cytarabine) (n = 1), or RMP (rituximab, high-dose MTX, and procarbazine; n = 5), and adjuvant radiotherapy (n = 2).
Local radiotherapy (n = 3 ), Rituximab-monotherapy (n = 1), or no treatment (n = 5).